Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2015

Filed with the SEC on Dec 10, 2015 and accepted by EDGAR at Dec 10, 2015, 16:47 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-08-01 to 2015-10-31$0us-gaap:Revenues
Revenue6 months2015-05-01 to 2015-10-31$0us-gaap:Revenues
Cost of revenue3 months2015-08-01 to 2015-10-31$0us-gaap:CostOfRevenue
Cost of revenue6 months2015-05-01 to 2015-10-31$0us-gaap:CostOfRevenue
Gross profit3 months2015-08-01 to 2015-10-31$0us-gaap:GrossProfit
Gross profit6 months2015-05-01 to 2015-10-31$0us-gaap:GrossProfit
Research and development3 months2015-08-01 to 2015-10-31$439.7kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2015-05-01 to 2015-10-31$595.4kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-08-01 to 2015-10-31−$1.1mus-gaap:OperatingIncomeLoss
Operating income6 months2015-05-01 to 2015-10-31−$2.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2015-08-01 to 2015-10-31$194us-gaap:InterestExpense
Interest expense6 months2015-05-01 to 2015-10-31$826us-gaap:InterestExpense
Net income3 months2015-08-01 to 2015-10-31−$1.1mus-gaap:NetIncomeLoss
Net income6 months2015-05-01 to 2015-10-31−$1.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2015-08-01 to 2015-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2015-05-01 to 2015-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2015-05-01 to 2015-10-31−$2.1mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2015-10-31$2.3mus-gaap:Cash
Current assetsAt period end2015-10-31$2.5mus-gaap:AssetsCurrent
Total assetsAt period end2015-10-31$7.6mus-gaap:Assets
Current liabilitiesAt period end2015-10-31$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-10-31$1.1mus-gaap:Liabilities
Shareholders' equityAt period end2015-10-31$6.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-15-004472. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.